BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Solitano V, D'Amico F, Zacharopoulou E, Peyrin-Biroulet L, Danese S. Early Intervention in Ulcerative Colitis: Ready for Prime Time? J Clin Med 2020;9:E2646. [PMID: 32823997 DOI: 10.3390/jcm9082646] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
Number Citing Articles
1 Alsoud D, Vermeire S, Verstockt B. Biomarker discovery for personalized therapy selection in inflammatory bowel diseases: Challenges and promises. Current Research in Pharmacology and Drug Discovery 2022. [DOI: 10.1016/j.crphar.2022.100089] [Reference Citation Analysis]
2 Solitano V, Armuzzi A. Editorial: STAT3 phosphorylation for tofacitinib monitoring in ulcerative colitis-a step towards precision medicine? Aliment Pharmacol Ther 2022;56:347-8. [PMID: 35748839 DOI: 10.1111/apt.17038] [Reference Citation Analysis]
3 Bouhuys M, Lexmond WS, Dijkstra G, Lobatón T, Louis E, van Biervliet S, Groen H, Guardiola J, Rheenen PV. Efficacy of anti-TNF dosing interval lengthening in adolescents and young adults with inflammatory bowel disease in sustained remission (FREE-study): protocol for a partially randomised patient preference trial. BMJ Open 2021;11:e054154. [PMID: 34732500 DOI: 10.1136/bmjopen-2021-054154] [Reference Citation Analysis]
4 Solitano V, D'Amico F, Fiorino G, Paridaens K, Peyrin-Biroulet L, Danese S. Key Strategies to Optimize Outcomes in Mild-to-Moderate Ulcerative Colitis. J Clin Med 2020;9:E2905. [PMID: 32911840 DOI: 10.3390/jcm9092905] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]